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ABSTRACT 
Trends in Prices of Insulin Marketed in the US 
by Hana A. Althobaiti 
INTRODUCTION: Diabetes mellitus is one of the most prevalent and costly chronic 
diseases in the United States (US). The healthcare and drug cost of diabetes has risen 
steadily and the increase in patients’ out-of-pocket drug expenditures are associated with a 
reduction in treatment adherence. The objectives of this study were to assess trends in 
insulin products prices in the period January 1983-July 2019, and to compare the price, 
acquisition costs and reimbursement amount of insulins available in the US.  
DATA AND METHODS: Data of insulin products marketed in the US during the period 
January 1983-July 2019 was derived from the FDA databases, the RedBook online, 
Medicaid.gov, the Department of Veterans Affairs, and the Centers for Medicare & 
Medicaid Services. Prices were adjusted using the consumer price index (CPI). The 
compounded average group rate (CAGR) was calculated for each insulin product. Data was 
analyzed by summary descriptive statistics. 
RESULTS: Human insulins had a CPI-adjusted AWP CAGR ranging 4.89%-8.89% from 
the first AWP effective date to July 2019 and insulin analogues had a CPI-adjusted AWP 
CAGR ranging 9.5%- 9.75%. The 2 follow-on (biosimilar) insulins; long-acting insulin 
glargine and rapid-acting insulin lispro experienced a negative adjusted CAGR (-1.20%,  
-33.70%, respectively). Insulin acquisition cost and reimbursement amounts showed a 
large variation when compared with the average wholesale (AWP) prices. The wholesale 
acquisition cost (WAC) was typically set at 83.33% of the AWP. Community pharmacies 
acquired insulins and analogues at a median of 80.27% of the AWP. Significant reductions 
in AWP were observed for Medicare Part D (78.80% of the AWP), and Federal Supply 
Schedule (FSS) /Big4 (25.89%). 
CONCLUSION: Manufacturer prices of insulins and analogues increased significantly 
during the period of 1983- July 2019. There are significant differences in the manufacturer 
prices, pharmacy acquisition costs and reimbursement rates of insulins and analogues.  
V 
 
 
TABLE OF CONTENTS 
Abstract ....................................................................................................................... IV 
Table of Contents ........................................................................................................ V 
List of Tables .............................................................................................................. VI 
List of Figures ............................................................................................................. VII 
List of Abbreviations ................................................................................................... VIII 
1. Introduction .............................................................................................................  1 
2. Objectives ...............................................................................................................  5 
3. Hypotheses ..............................................................................................................  6 
4. Material and Methods ..............................................................................................  7 
5. Results..................................................................................................................... 13 
6. Discussion ............................................................................................................... 25 
7. Conclusions ............................................................................................................. 30 
8. References ............................................................................................................... 31 
Appendices.................................................................................................................. 36 
VI 
 
 
LIST OF TABLES 
Table 1: Insulin prices per 30-DDD at market entry and July 1, 2019  
(CPI-Adjusted) ............................................................................................................ 15  
Table 2: Comparison of Insulin Prices in the US at July 1, 2019 .................................. 22 
  
VII 
 
 
 
LIST OF FIGURES 
 
Figure 1: Trends in AWP prices for Human insulin products ....................................... 17  
Figure 2: Trends in AWP prices for insulin analogue products..................................... 19 
Figure 3:  Comparison of Insulin Prices in the US at July 1, 2019 ................................ 24                            
 
        
  
VIII 
 
LIST OF ABBREVIATIONS 
 
ACA:      Affordable Care Act 
ATC:      Anatomical Therapeutic Chemical 
AWP:     Average Wholesale Price 
CAGR:   Compound Annual Growth Rate 
CMS:     Centers for Medicare & Medicaid Services 
CPI:     Consumer Price Index 
DDD:     Defined Daily Dose 
FDA:     Food and Drug Administration 
FSS:       Federal Supply Schedule 
NADAC:  National Average Drug Acquisition Cost 
NDC:       National Drug Code 
NPH:       Neutral Protamine Hagedorn 
US:      United States 
WAC:       Wholesale Acquisition Cost 
WHO:      World Health Organization
1 
 
 
1. INTRODUCTION 
Diabetes mellitus is one of the most prevalent and costly chronic diseases in the 
United States (US). It was estimated that 9.7% of the US adult population had a diagnosis 
of diabetes mellitus in 2017.1The total health care cost of diagnosed diabetes was estimated 
at $327 billion in the US in 2017.2 This cost included $237 billion in direct costs and $90 
billion in indirect costs. Similar to estimates in 2007 and 2012, patients who were 
diagnosed with diabetes spent 2.3 times more in health care compared with those without 
diabetes. Between 2002 and 2011 patients with diabetes had significantly higher health 
expenditures than those without diabetes and the leading causes of high expenditures were 
hospitalization and medications.3 Furthermore, from 2012 to 2017 the healthcare cost of 
diabetes increased by 26% due to the increased prevalence of diabetes and the increased 
cost per person with diabetes.2    
The cost of diabetes has risen steadily in the past decades due to a combination of 
factors, including the increasing number of patients, the growing complexity of care, and 
the high prices of antidiabetic drugs.4,5 The high prices of new antidiabetic drugs also result 
in formulary restrictions that restrict access to care and increase the administrative burden 
and the cost of providing diabetes care.6,7 In 2011, one-fourth of  patients with diabetes had 
high family out-of-pocket expenditures burden; the median out of pocket costs per 
prescription for all insulins increased from $19 in 2000 to $36 in 2010.8 Increasing patient’s 
out-of-pocket expenditures is associated with a significant reduction in adherence to drug 
therapy.7,9-11 
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Insulin is widely used today in patients with type 1 or type 2 diabetes and is 
arguably the most effective and predictable of all of the current antihyperglycemic agents. 
The cost of insulin treatment is high, and the growing number of patients with diabetes 
using insulin presents a financial challenge to health care payers and patients. The total 
cost of insulin and other antidiabetic medications increased by 45% from 2012 to 2017, 
and the inflation-adjusted cost of insulin increased by 110% during the same period.2 A 
recent study found that the estimated expenditures per patient for insulin increased in 2013 
in the US compared with oral antihyperglycemics based on a nationally represented 
survey.12  
The price of insulin for  government programs have also increased. The Center for 
Medicare and Medicaid Services (CMS) estimated that 32% of all Medicare spending 
could be attributed to patients with diabetes.9 Medicare Part D spending on insulins has 
shown an increasing and accelerating trend. As spending on insulins has increased, so too 
have patient out-of-pocket costs.13 Between 2007 and 2017, average out-of-pocket costs 
per insulin user among Medicare Part D enrollees increased fourfold for insulin. 
Comparatively, Medicare Part D spending per insulin increased by 280% over the same 
period.14 
The Affordable Care Act (ACA) was passed by Congress and signed into law by 
President Obama in 2010. One of the main motivating reasons for this act was to provide 
health insurance to approximately 40 million Americans who were not covered by some 
insurance. It was also designed to address specific deficiencies in the healthcare system. 13 
A published study in 2018 concluded that health insurance coverage among adults with 
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diabetes age 18–64 years increased significantly after implementation of the ACA, and 
medical costs to families decreased, especially among those with lower incomes. 15 
The increase in the cost of antidiabetic drugs has important clinical implications 
such as low adherence to these medications.16 Adherence to antidiabetic drug therapy is 
vital to control blood glucose and prevent diabetic complications.9,16 Low adherence results 
in an increase in diabetic complications and diabetes-related health care expenditures.2,4,17. 
Evidence from the study by Caro et al. indicated that diabetic complications were a large 
share of the total health costs of patients with type 2 diabetes.18 Previous studies also 
indicated that poor adherence was associated with high healthcare costs of diabetes.19-21 
Lau et al. found that patients with type 2 diabetes with low adherence over one year were 
at a higher risk of hospitalization.22 Furthermore, another study indicated that medication 
noncompliance was associated with increased all-cause mortality in patients with type 2 
diabetes.23 
 Affordability of insulin has become the main problem for insulin users in the US. 
The availability of follow-on (biosimilar) insulins represents an opportunity to lower 
treatment costs since biosimilars are typically marketed at a lower price than the respective 
reference biological products. 24,25A reduction in price has been noticed when biosimilars 
of other drugs entered into the market, so it is expected that the market introduction of 
biosimilar insulins will also result in a reduction in the price of insulin. 26 
In light of current evidence, finding the way to slow down the increasing rate of 
insulin product costs would be necessary. Prior research examined price differences of 
branded prescription drug prices among several OECD (Organization for Economic Co-
4 
 
Operation and Development) countries and the US and factors that could affect prescription 
drug wholesale acquisition cost.27,28  
 To our knowledge, no study has assessed trends in insulin product prices in the 
US over a long period of time. 
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2. OBJECTIVES 
 
The objectives of this study were to assess trends in insulin products prices in the 
period January 1983-July 2019, and to compare the price, acquisition costs and 
reimbursement amount of insulins available in the US.  
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3. HYPOTHESIS 
 
We hypothesize that the prices of insulins marketed in the US increased faster than the 
inflation during the period of 1983- July 2019 
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4. MATERIAL AND METHODS 
 
4.1. Data Sources 
Data for all insulin products marketed in the US during the period 1983-July 2019 
were collected from the FDA databases, the RedBook online, Medicaid.gov, the 
Department of Veterans Affairs, and the CMS.  
Insulin products were classified using levels 2 (i.e., therapeutic subgroup) of the 
anatomical therapeutic chemical classification (ATC) system from the World Health 
Organization Collaborating Centre for Drug Statistics Methodology.29 Defined daily dose 
(DDD) data for each insulin was collected from the World Health Organization 
Collaborating Centre for Drug Statistics Methodology.  If the DDD was not available, the 
recommended dose was collected from the FDA-approved drug label. The maximum dose 
was used when the recommended dose was not included in the label. DDD is a technical 
unit of measurement and comparison in drug utilization studies.30 DDD was first 
recommended in 1969 by WHO with the ATC classification system for comparing data on 
drug consumption. DDD defines as “the assumed average dose per day for a drug used in 
its main indication in adults”. 31 It does not represent the recommend or actual dose. DDD 
is suitable for long-term studies to compare relative changes in drug usage and studies for 
costs, not for clinical consequences. Therefore, DDD is appropriate for economic studies.32, 
33 
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Prices data as of July 2019 were retrieved from the RedBook online which included 
product name, price start date, deactivated status, deactivated date, active ingredient, 
manufacturer or distributor, generic or brand status, Orange Book code, code type, 
identifier, formulation, strength, route, package size, unit dose, average wholesale price 
(AWP) packaging price, and AWP unit price.34 All AWP changes and their respective 
effective dates were collected from the first AWP effective date to the last available AWP 
effective date. AWP is reported by the manufacturers and, although it does not represent 
the actual acquisition cost because of the discounts and rebates that happen in the market, 
it has been the primary drug payment benchmark for brand name products for a long time 
in the US.35,36  In most states, Medicaid uses the AWP to calculate the estimated acquisition 
costs used for outpatient pharmacy reimbursement. 37 However, AWP tends to be 20% or 
25% higher than the WAC, implying that WAC is usually 16.7% or 20% lower  than AWP. 
The presence of an AWP for drug products, whether supplied by the manufacturer or 
estimated by the price catalogs, transaction prices involving wholesalers, PBMs, 
pharmacies and other providers could all be specified with reference to AWP minus some 
% discount. The important point is that even though few if any transactions actually took 
place at the AWP price, the AWP serves a valuable role as a common reference point from 
which various discounts could be negotiated.38 In practice, the actual transaction prices 
paid to the pharmacy by third-party payers for brand drugs are typically established using 
the AWP minus a percentage discount.38  Even though some observers accurately called 
AWP “Ain‟t What‟s Paid,” AWP played a critical role in facilitating efficiently millions 
of transactions among the various manufacturers, providers, and payers.39  Therefore, 
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assessing AWP trends is useful to evaluate trends in prices and the burden of insulin costs 
on payers and patients. 
National Average Drug Acquisition Cost (NADAC) data of insulin products in July 
2019 were collected from Medicaid.gov.40 NADAC data included national drug code 
(NDC), NADAC per unit, effective date, and pricing unit. NADAC is produced by the 
retail community pharmacy survey to give a better benchmark of estimated acquisition 
costs to Medicaid.40 NADAC reflects the prices paid by retail community pharmacies to 
acquire prescription and over-the-counter covered outpatient drugs.40 The NADAC is used 
by Medicaid for estimating the reimbursement to community pharmacies for the drug 
product. 
Negotiate prices for insulin products used by the Federal Government were retrieved 
from the Department of Veterans Affairs. The VA is charged with negotiating prices, called 
the Federal Supply Schedule (FSS), for all federal direct healthcare payer agencies (not 
including Medicare and Medicaid).41 In addition to the FSS, the VA can receive additional 
statutorily defined rebates through their shared purchasing power with other large agencies 
(the Big 4 price) and additional rebates for themselves through preferred formulary 
placement (national contract price). For certain drugs, the VA receives even lower prices 
for the Big 4 public payers: “Big 4 Price”. In general, FSS contracts are multi-year 
(minimum of five years) and multiple award contracts, which means multiple companies 
supplying comparable products and services, at varying prices, are awarded contracts.42 
Pharmaceutical companies provide a discount to the federal government based on the 
lowest prices charged to private sector customers.43 Big 4 prices are only available to the 
VA, Department of Defense, Public Health Service (Indian Health Service), and U.S. Coast 
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Guard customers and are based on pricing calculations outlined under the Public Law.43 
The following information was collected from the VA: NDC, package, contract number, 
vendor, generic name, trade name, and FSS and Big4 price. 
 Prices information was obtained from the CMS Medicare Part D as this data is 
available online to the general public from the CMS website. 44 The CMS website contains 
information about annual medication spending and utilization, but it does not include cost 
information for individual dosages. Instead, it provides total spending for each medication 
aggregated to the active ingredient unit, broken down by year. CMS is prohibited from 
publicly disclosing specific information on manufacturer rebates; thus, the data used to 
select Part D drugs do not reflect any manufacturers’ rebates or other price concessions.44 
The average spending per dosage unit (weighted) for 2017 was collected based on the brand 
and generic names for insulin products.   
 
 
 
11 
 
 
4.2. Methods 
The AWP per 30-DDD (AWP 30-DDD) was calculated and then adjusted to 2019 
dollars (adjusted AWP 30-DDD) using the consumer price index (CPI) of all urban 
consumers from the Bureau of Labor Statistics.45 We assumed daily use of 40 IU of insulin 
per day (0.4 NDC units) based on the standard established by the WHO (ATC) 
classification system guidelines for the defined daily dose of basal insulin.29 Assuming use 
of only 1 insulin product at a time and no wasted insulin, the typical diabetic in this study 
would require 1200 IU (40 IU/d × 30 d/mo) of insulin per 1 month. For the inhaled insulin, 
insulin human inhaled KIT 1 mg/1 actuation; 3 mg/3, marketed by PFIZER U.S. 
PHARMACEUTICALS GROUP, 1mg inhaled insulin ≈ 3 IU of subcutaneously injected 
regular insulin. We assumed that the required daily dose of the inhaled insulin is equal to 
the maximum dose = 16 IU. Therefore, the typical diabetic in this study would require 480 
IU (16 IU/d × 30 d/mo) of inhaled insulin per 1 month.    
The total percentage increase and the compound annual growth rate (CAGR) were 
calculated from the adjusted AWP 30-DDD on the first effective date to the adjusted AWP 
30-DDD in July 2019 or the last effective date when the drug discontinued. The CAGR 
was used to compare the year-over-year drug price growth rate over different time periods. 
CAGR was calculated by using the following formula: 
CAGR= (EB/BB)1/N −1 
Where: 
EB = the adjusted AWP 30-DDD in the last effective date  
12 
 
BB = the adjusted AWP 30-DDD on the first effective date 
n=Number of years 
 
The NADAC per 30-DDD was calculated and then adjusted to 2019 dollars. The 
percentage of adjusted NADAC per 30-DDD with respect to the adjusted AWP per 30-
DDD was calculated to assess the relationship between these two prices. 
Prices data for all strengths and package types for each insulin were collected, then 
one strength and package type were selected to represent each drug. The strength closest 
to the DDD, and package type closest to 100-unit package type, if several were available, 
were included in the analysis. We excluded regular human insulin, U-500 (concentrated) 
(Eli Lilly and Company) due to its atypical dosage strength. Humulin R U-500 is different 
from all other insulin products because it contains 500 IU per 1mL of solution; other insulin 
products typically contain 100 IU per 1mL. 
Summary descriptive statistics were computed to describe insulin product price 
trends. Comparisons of insulin prices from the different data sources were performed using 
the AWP as the reference for price comparisons.  All analyses were performed using 
Microsoft Excel 2016.  
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5. RESULTS 
Insulin products 
During the study period (1983-July 2019), there were 86 insulin products marketed 
in the US; 40.4% (n=36) of the marketed insulin were available as over-the-counter (OTC) 
medications, and 59.6% (n=53) were available as prescribed medications.  Five types of 
insulin are available based on their onset and duration of action.  These are rapid-acting 
insulin (glulisine, lispro, aspart), regular or short-acting insulin (e.g., human regular), 
intermediate-acting insulin (NPH), long-acting insulin (detemir, glargine) and ultra-long-
acting insulin (degludec). There are also premixed insulins on the market which contain 
rapid-acting or short-acting insulin and an intermediate-acting insulin analogue, as well as 
long-acting or ultra-long-acting insulin formulated with a noninsulin drug. All animal-
sourced insulins (n=12) were discontinued from the US market by April 2006. The final 
analytical sample included 28 insulin products with complete data.  
The adjusted AWP total percentage increase and CAGR from approval to July 2019 
or drug discontinuation date were positive for all insulin products except for the follow on- 
insulins (biosimilar), and one of the inhaled insulins (Table 1).  The premixed insulin 
(insulin-GLP-1 receptor agonist combinations; insulin glargine/lixisenatide and insulin 
degludec/liraglutide had the lowest adjusted AWP CAGR (1.83%, 1.00%) among all 
insulin products marketed in the US during the study period.  
All human insulin preparations (insulin human regular solution, insulin human 
isophane (NPH), and insulin human isophane (NPH)/insulin human regular) were on the 
14 
 
market on July 2019; they entered to the US market at lower price than other insulins 
(adjusted AWP 30-DDD, ranging from $79.04 to $95.27). Human insulins, not including 
inhalation formulations, had the adjusted AWP CAGR ranging from 4.89%-8.89% (n=6). 
The adjusted AWP 30-DDD for human insulins was very similar ($530.82 and $491.55, 
respectively) for the six products marketed by two different companies in July 2019, 
irrespective of short, intermediate, and combined acting insulin forms (Table1).  
Human insulins also showed similar trends in the average AWPs and effective dates 
over the study period (Figure 1).  For example, the cost of Eli Lilly’s human insulins 
increased from $ 202.90 for 100 units/ml vial in 2011 to $ 535.32 in July 2019.  Likewise, 
the price of Novo Nordisk’s human insulins increased from $205.33 for 100 units/ml vial 
in 2011 to $ 495.72 in July 2019. However, Novo Nordisk and Eli Lilly had similar price 
trends until 2016 (Figure 1).   
15 
 
Table 1. Insulin prices per 30-DDD at market entry and July 1, 2019 (CPI-Adjusted) 
 
  
Drug Class 
RedBook  
First 
Date 
 RedBook First 
AWP 30-DDD 
RedBook
 Last 
Date 
RedBook Last  
AWP 30-DDD 
 AWP 
 Increase 
CPI  
CAGR 
NADAC  
30-DDD 
 Jul 1, 
2019 
NADAC/ 
AWP 
Jul 1, 2019 
Fast-Acting Insulins 
insulin aspart sol 100 u/1ml Novo Nordisk, 
Inc. 8/27/2001 $205.11 7/1/2019 $1,032.92 403.6% 9.5% 
 
$826.25 
 
80.0% 
insulin glulisine sol 100 u/1ml Sanofi-
Aventis U.S. Llc 1/24/2006 $298.79 7/1/2019 $1,013.62 239% 9.5% 
 
$811.50 
 
80.06% 
insulin lispro sus 100 u/1ml Lilly, Eli & 
Company 7/24/1996 $121.44 7/1/2019 $980.60 707% 9.5% 
 
$777.54 
 
79.29% 
** insulin lispro, recombinant sol 100 
u/1ml Sanofi-Aventis U.S. Llc. 1/1/2018 $862.80 7/1/2019 $466.77 -46% -33.7% 
 
$374.07 
 
80.14% 
Short--Acting Insulins 
insulin human regular sol 100 u/1ml Lilly, 
Eli & Company 
6/16/1986 $86.57 7/1/2019 $530.82 513.17% 5.6% $432.83 81.54% 
insulin human regular sol 100 u/1ml Novo 
Nordisk, Inc. 
10/14/1991 $88.60 7/1/2019 $491.55 454.80% 6.4% $399.51 81.28% 
insulin pork regular sol 100u/1ml Lilly, Eli 
& Company 
12/22/1986 $110.44 4/1/2006 $181.74 64.56% 2.6% NA NA 
insulin pork regular sol 100u/ml Novo 
Nordisk, Inc. 
9/1/1987 $96.23 2/7/2000 $207.35 115.47% 6.4% NA NA 
Intermediate- Acting Insulins 
insulin human isophane (nph) sus 100 
u/1ml Lilly, Eli & Company 
6/27/1983 $95.27 7/1/2019 $530.82 457.17% 4.89% $433.12 81.60% 
insulin human isophane (nph) sus 100 
u/1ml Novo Nordisk, Inc. 
12/1/1987 $79.04 7/1/2019 $491.55 521.90% 5.96% $400.27 81.43% 
insulin pork isophane (nph) sus 100u/1ml 
Lilly, Eli & Company 
12/22/1986 $110.44 4/1/2006 $181.74 64.56% 2.62% NA NA 
insulin pork isophane (nph) sus 100u/1ml 
Novo Nordisk, Inc. 
9/1/1987 $96.23 2/7/2000 $207.35 115.47% 6.37% NA NA 
insulin beef zinc (lente) sus 100u/1ml Novo 
Nordisk, Inc. 
2/12/1987 $60.80 10/20/1994 $73.21 20.41% 2.45% NA NA 
insulin pork zinc (lente) sus 100u/1ml Novo 
Nordisk, Inc. 
 
9/1/1987 $96.23 2/7/2000 $207.35 115.47% 6.37% NA NA 
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Drug Class 
RedBook  
First 
Date 
 RedBook First 
AWP 30-DDD 
RedBook
 Last 
Date 
RedBook Last  
AWP 30-DDD 
 AWP 
 Increase 
CPI  
CAGR 
NADAC  
30-DDD 
 Jul 1, 
2019 
NADAC/A
WP 
Jul 1, 2019 
Long-Acting Insulins 
insulin degludec sol 100 u/1ml Novo 
Nordisk, Inc. 
10/23/2015 $1,139.47 7/1/2019 $1,209.97 6.19% 1.64% $986.09 81.50% 
insulin detemir sol 100 u/1ml Novo 
Nordisk, Inc. 
2/6/2006 $321.50 7/1/2019 $1,099.98 242.14% 9.62% $894.68 81.34% 
insulin glargine recombinant sol 100 u/1ml 
Sanofi-Aventis U.S. Llc 
5/1/2001 $186.88 7/1/2019 $1,012.22 441.64% 9.75% $824.20 81.42% 
** insulin glargine recombinant sol 100 
u/1ml Lilly Usa, Llc. 
11/17/2016 $801.59 7/1/2019 $776.67 -3.11% -1.20% $647.84 83.41% 
Premixed; Intermediate-or Long-Acting Combined with Fast- or Short-Acting Insulins 
insulin degludec, liraglutide sol 100 u/1ml-
3.6 mg/1ml Novo Nordisk, Inc. 
11/21/2016 $2,411.42 7/1/2019 $2,474.72 2.63% 1.00% $ 1,986.84 80.29% 
insulin glargine, recombinant/lixisenatide 
sol 100 u/1ml-33 mcg/1ml Sanofi-Aventis 
U.S. Llc 
12/12/2016 $1,605.93 7/1/2019 $1,681.97 4.73% 1.83% $1,349.44 80.23% 
insulin aspart protamine/insulin aspart sus 
70 u/1ml-30 u/1ml Novo Nordisk, Inc. 
9/11/2002 $306.03 7/1/2019 $1,329.91 334.57% 9.14% $1,064.91 80.07% 
insulin human isophane (nph)/insulin 
human regul sus 70 u/1ml-30 u/1ml Lilly, 
Eli & Company 
6/26/1989 $83.46 7/1/2019 $530.82 536.02% 6.36% $431.90 81.37% 
insulin human isophane (nph)/insulin 
human regul sus 70 u/1ml-30 u/1ml Novo 
Nordisk, Inc. 
10/14/1991 $88.60 7/1/2019 $491.55 454.8% 6.38% $399.30 81.23% 
insulin lispro protamine/insulin lispro sus 
75 u/1ml-25 u/1ml Lilly, Eli & Company 
12/11/2000 $209.23 7/1/2019 $1,016.30 385.73% 8.89% NA NA 
insulin beef regular/insulin pork isophane 
(nph) sus 100u/1ml Lilly, Eli & Company 
12/22/1986 $67.62 12/10/1999 $128.11 89.46% 5.05% NA NA 
insulin beef regular/insulin pork zinc (lente) 
sus 100u/1ml Lilly, Eli & Company 
12/22/1986 $67.62 12/10/1999 $128.11 89.46% 5.05% NA NA 
Inhaled insulins 
insulin human inhaled aro 4 u MannKind 
and MannKind Cares 
7/15/2016 $1,147.24 7/1/2019 $1,545.40 34.71% 10.59% NA NA 
insulin human inhaled;insulin human 
inhaled KIT 1 mg/1 actuation; 3 mg/2 
Pfizer 
6/20/2006 $374.49 1/31/2008 $359.98 -3.87% -2.42% NA NA 
Acronym: sol-solution, sus-suspension, and aro-aerosol powder.  * Last effective date is 7/1/2019 or discontinuation date, if it is not on the market as of 7/1/2019.  ** Follow-on 
(Biosimilar) insulin 
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Figure 1.  Trends in AWP prices for Human insulin products  
AWP: Average wholesale price, DDD: Daily defined dose 
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All insulin analogues (insulin lispro, insulin aspart, insulin glulisine, insulin 
degludec, insulin glargine, and insulin detemir) remained in the market as of July 2019, 
and they had the highest adjusted AWP CAGR (9.5%- 9.75%) among all insulin products, 
excluding insulin degludec. The two fast-acting insulin analogues, insulin aspart and 
insulin glulisine, had similarly adjusted AWP 30-DDD ($1,032.92 and $1,013.62, 
respectively) for the two sponsor companies marketing these products on July 2019 (Table 
1). On the contrary, the fast-acting insulin lispro had the lowest adjusted AWP 30-DDD 
($980.60) among insulin analogues in July 2019 (Table 1).    
The adjusted AWP 30-DDD for long-acting insulin analogues marketed by two 
different companies, insulin glargine and insulin detemir, was similar ($1,012.22, 
$1,099.98, respectively) on July 2019 (Table 1). The adjusted AWP total percentage 
increase and CAGR for insulin degludec were the lowest compared to other long-acting 
insulins (1.64% vs. 9.62%, 9.75%) (Table 1). 
Fast-acting insulin and long-acting analogues also had similar upward trends in the 
AWP during the study period.  Similarly to human insulin product prices trends, the 3 
competitor companies adopted similar price increases during the study period (Figure 2). 
However, for fast-acting insulins, Novo Nordisk was  adopted similar pricing trends than 
Eli Lilly until 2017 when Novo Nordisk’s insulin prices increased faster than Lilly spiked 
up. A similar practice noticed with long-acting insulins (Figure 2). 
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Figure 2.  Trends in AWP prices for insulin analogue products and their follow-on 
insulins 
AWP: Average wholesale price, DDD: Daily defined dose 
** Follow-on (Biosimilar) insulin 
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The first two rapid-acting inhaled insulins marketed in the US were Exubera 
(approved in 2006), and Afrezza (approved in 2014). Pfizer withdrew Exubera from the 
market in October 2017 when it failed to gain acceptance from patients and providers.  
Afrezza is the only inhaled human insulin remaining in the US market in July 2019 with 
the adjusted AWP 30-DDD of $1,545.40 and the adjusted AWP CAGR of 10.59% from 
approval to July 20219.  
The two follow-on (biosimilar) insulins, long-acting insulin glargine and rapid-
acting insulin lispro experienced a negative adjusted CAGR (-1.20%, -33.70%, 
respectively) from the approval date to July 2019. However, the CAGR for all animal 
insulins from approval to discontinuation date was ranging from 2.6% to 6.4%. 
AWP and NADAC for Insulin products 
In the study period, there were 18 insulin products drugs as collected by NADAC 
data in July 2019 (Table 1). The average of NADAC per 30-DDD as a percentage of the 
AWP per 30-DDD in July 2019 was 80.47% ranging from 79.29% to 81.54% (Table 1). 
Comparison of insulin prices from the different data sources  
The prices of insulin products showed a significant variation in comparison with 
the AWP price (Table 2). The WAC was set at 83.33% of the AWP for all insulins and 
analogues. Community pharmacies (independent and chains) were able to acquire the 
insulins at a median NADAC of 80.27% of the AWP. However, pharmaceutical companies 
provided additional discounts to the FSS and the Big 4 that paid for insulins at a median of 
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25.89% of the AWP price for both FSS and Big4. The FSS and the Big 4 were able to pay 
13.6% of the AWP for insulin lispro and 22.7% of the AWP for insulin glargine.  
For Medicare Part D, the adjusted average price of AWP in 2017 was compared to 
the adjusted insulins price of Medicare part D during the same period to have a head to 
head comparison. Medicare Part D was able to acquire the insulins at a median of 78.8% 
of the AWP ranging from 54.2% to 98.7% (Table 2).  
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Table 2. Comparison of Insulin Prices in the US at July 1, 2019 
 
Drug Class 
 
First 
effective 
date  
 
Effective 
Date 
 
AWP CPI 
 
FSS/AWP, 
% 
 
Big 
4/AWP, 
% 
 
NADAC/
AWP, % 
 
WAC/ 
AWP, % 
 
AWP (2017) 
 
Part D/AWP 
 
Fast-Acting Insulins 
insulin aspart sol 100 u/1ml Novo Nordisk, 
Inc. 8/27/2001 7/1/2019 
$ 34.43 28% 28% 80% 83% $     34.54 83% 
insulin glulisine sol 100 u/1ml Sanofi-
Aventis U.S. Llc 1/24/2006 7/1/2019 
$ 33.79 30% 33% 80% 83% $     32.07 81% 
insulin lispro sus 100 u/1ml Lilly, Eli & 
Company 7/24/1996 7/1/2019 
$ 42.07 14% 14% 81% 83% $     34.27 77% 
** insulin lispro, recombinant sol 100 
u/1ml Sanofi-Aventis U.S. Llc. 1/1/2018 7/1/2019 
$ 15.56 79% 79% 80% 83% NA NA 
Short--Acting Insulins 
insulin human regular sol 100 u/1ml Lilly, 
Eli & Company 
6/16/1986 7/1/2019 $     17.69 9% 9% 82% 83% $    18.55 54% 
insulin human regular sol 100 u/1ml Novo 
Nordisk, Inc. 
10/14/1991 7/1/2019 $     16.38 17% 17% 81% 83% $    17.31 64% 
insulin pork regular sol 100u/1ml Lilly, Eli 
& Company 
12/22/1986 4/1/2006 $        7.14 NA NA NA 83% NA NA 
insulin pork regular sol 100u/ml Novo 
Nordisk, Inc. 
9/1/1987 2/7/2000 $        7.14 NA NA NA 80% NA NA 
Intermediate- Acting Insulins 
insulin human isophane (nph) sus 100 
u/1ml Lilly, Eli & Company 
6/27/1983 7/1/2019 $     17.69 9% 9% 82% 83% $    18.55 54% 
insulin human isophane (nph) sus 100 
u/1ml Novo Nordisk, Inc. 
12/1/1987 7/1/2019 $     16.38 17% 17% 81% 83% $    17.31 64% 
insulin pork isophane (nph) sus 100u/1ml 
Lilly, Eli & Company 
12/22/1986 4/1/2006 $        7.14 NA NA NA 83% NA NA 
insulin pork isophane (nph) sus 100u/1ml 
Novo Nordisk, Inc. 
9/1/1987 2/7/2000 $        7.14 NA NA NA 80% NA NA 
insulin beef zinc (lente) sus 100u/1ml Novo 
Nordisk, Inc. 
2/12/1987 10/20/1994 $        2.47 NA NA NA 80% NA NA 
insulin pork zinc (lente) sus 100u/1ml Novo 
Nordisk, Inc. 
9/1/1987 2/7/2000 $        7.14 NA NA NA 80% NA NA 
Long-Acting Insulins 
insulin degludec sol 100 u/1ml Novo 
Nordisk, Inc. 
10/23/2015 7/1/2019 $     40.33 73% 52% 80% 83% $    37.20 83% 
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Drug Class 
 
First 
effective 
date  
 
Effective 
Date 
 
AWP CPI 
 
FSS CPI, 
% 
 
Big 4 CPI, 
% 
 
NADAC, 
% 
 
WAC, % 
 
AWP CPI 
(2017) 
 
Part D 
CPI 
Long-Acting Insulins 
insulin detemir sol 100 u/1ml Novo 
Nordisk, Inc. 
2/6/2006 7/1/2019 $     36.67 57% 48% 80% 83% $    33.82 83% 
insulin glargine recombinant sol 100 u/1ml 
Sanofi-Aventis U.S. Llc 
5/1/2001 7/1/2019 $     33.74 22.7% 22.7% 87% 83% $    31.70 81% 
** insulin glargine recombinant sol 100 
u/1ml Lilly Usa, Llc. 
11/17/2016 7/1/2019 $     25.89 64% 63% 80% 83% $    26.94 82% 
Premixed; Intermediate-or Long-Acting Combined with Fast- or Short-Acting Insulins-or non-insulin drug  
insulin degludec, liraglutide sol 100 u/1ml-
3.6 mg/1ml Novo Nordisk, Inc. 
11/21/2016 7/1/2019 $     82.49 75% 59% 80% 83% $    79.89 NA 
insulin glargine, recombinant/lixisenatide 
sol 100 u/1ml-33 mcg/1ml Sanofi-Aventis 
U.S. Llc 
12/12/2016 7/1/2019 $     56.07 79% 57% 80% 83% $    53.22 NA 
insulin aspart protamine/insulin aspart sus 
70 u/1ml-30 u/1ml Novo Nordisk, Inc. 
9/11/2002 7/1/2019 $     44.33 26% 26% 80% 83% $    44.47 66% 
insulin human isophane (nph)/insulin 
human regul sus 70 u/1ml-30 u/1ml Lilly, 
Eli & Company 
6/26/1989 7/1/2019 $     17.69 9% 9% 81% 83% $    18.55 71% 
insulin human isophane (nph)/insulin 
human regul sus 70 u/1ml-30 u/1ml Novo 
Nordisk, Inc. 
10/14/1991 7/1/2019 $     16.38 17% 17% 81% 83% $    17.31 60% 
insulin lispro protamine/insulin lispro sus 
75 u/1ml-25 u/1ml Lilly, Eli & Company 
12/11/2000 7/1/2019 $     33.88 17% NA 80% 83% $    35.52 80% 
insulin beef regular/insulin pork isophane 
(nph) sus 100u/1ml Lilly, Eli & Company 
12/22/1986 12/10/1999 $        4.37 NA NA NA 83% NA NA 
insulin beef regular/insulin pork zinc (lente) 
sus 100u/1ml Lilly, Eli & Company 
12/22/1986 12/10/1999 $        4.37 NA NA NA 83% NA NA 
Inhaled insulins 
insulin human inhaled aro 4 u MannKind 
and MannKind Cares 
7/15/2016 7/1/2019 $        4.38 13% NA NA 83% $      3.79 98.74% 
insulin human inhaled;insulin human 
inhaled KIT 1 mg/1 actuation; 3 mg/2 
Pfizer 
6/20/2006 1/31/2008 $     12.57 NA NA NA 83% NA NA 
Acronym: sol-solution, sus-suspension, and aro-aerosol powder.   ** Follow-on (Biosimilar) insulin
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Figure 3: Comparison of Insulin Prices in the US at July 1, 2019 
AWP: Average wholesale, FSS: Federal Supply Schedule, NADAC: National Average Drug Acquisition Cost, WAC: Wholesale Acquisition 
Cost 
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6. Discussion  
To our knowledge, this is the first study assessing price trends for insulin products and 
comparing different manufacturer prices, actual transaction cost estimation, and 
reimbursement amounts available in the US.  The study results showed that prices of insulin 
products increased faster than the inflation during the study period. Likewise, previous 
studies have found that prices for widely used brand name prescription drugs increased 
substantially faster than inflation over the past 14 years.28, 46 
Additionally, the results of this study have confirmed that manufacturer listed prices 
(AWP and WAC) are representative of the actual transaction price paid by community 
pharmacy for insulin. The AWP and WAC are benchmark prices used in the US for 
reimbursement purposes. However, the WAC is closely related to the actual transaction 
price paid by community pharmacies for insulin products.  
We also found that the list price of competing insulin formulations has appeared to rise 
in tandem, and companies do not engage in price competition at the level of the community 
pharmacy. The price trends of insulin products within the same pharmacological class were 
very similar until 2016.  For instance, human insulins marketed by two different 
pharmaceutical companies showed very similar price trends.  Prices of fast-acting insulin 
analogues, excluding follow on (biosimilar) insulins, also showed very similar prices and 
price trends. Moreover, the price of long-acting insulin analogues, insulin glargine, and 
insulin detemir has been the same, even though they were marketed by different 
pharmaceutical companies.  There has been a pattern of increasing prices overtime for all 
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available insulin products. A previous study found that detemir has increased in price over 
time and in parallel with the price of insulin glargine. 47 In practice, however, competition 
between 2 or more brand name manufacturers selling drugs in the same class does not 
usually result in substantial price reductions.48 Thus, insulins and analogues experience a 
similar trend in price competition.  This phenomenon likely arises from limited market 
competition.  
Of note, more than 90 years have passed since insulin was first clinically used in a 
patient with diabetes; and currently, there are still no generic insulin options available in 
the US.49 Addressing the Challenges and Constraints of Insulin Sources and Supply 
(ACCISS) study reported that the global insulin market is controlled by the same three 
large multinational corporations that manufacture and sell insulin in the US. Eli Lilly, Novo 
Nordisk, and Sanofi represent 99% of the total insulin by value, 96% by total market 
volume, and 88% of global product registration.50 These 3 companies control the 
marketplace and face no real generic competitor to drive down prices.  With this level of 
market control and the absence of competition, there is nothing to stop the current 
companies from raising prices. So, the availability of generic insulin could substantially 
reduce overall spending and out-of-pocket costs. It would also improve patient adherence 
and reduce the financial burden on payers. However, the results of this study showed that 
the trends of insulins prices have changed during the last five years; pharmaceuticals 
companies stopped shadow pricing since 2015.  
Additionally, we found substantial differences in the prices of insulins used in the US 
healthcare system. The pharmaceutical companies listed prices were higher than the 
estimated acquisition costs (NADAC) and also higher than the prices used for 
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reimbursement (Medicaid Part D, FSS, and Big 4). The prices paid by the federal 
government were substantially lower than the prices paid in the private sector. The FSS 
and the Big 4 are prices negotiated by the Federal government for federal purchases of 
pharmaceuticals. The FSS and the Big 4 prices are based on the lowest prices offered in 
the private sector, and they are used by federal agencies for reimbursement purposes. 51  
Medicare Part D was able to acquire insulin products at a median slightly lower than the 
WAC, however the estimated Medicare Part D prices do not consider rebates obtained from 
manufactures by Medicare Part D plans. Medicare Part D spending on insulins has shown 
an increasing and accelerating trend during the past years.14 Among all insulin products, 
Part D spending was highest for insulin glargine, a long-acting insulin, with $2.6 billion in 
Part D spending in 2017.14   
Congress included a provision in the law that created the Medicare drug benefit 
program, prohibiting the Centers for Medicare & Medicaid Services from negotiating drug 
prices or from interfering with negotiations between individual Part D vendors and drug 
companies. This made prescription drugs under Part D one of the few Federal healthcare 
programs for which Centers for Medicare & Medicaid Services do not negotiate or set 
prices.52 
Insulins are regulated as biosimilar drugs in the European Union and as chemical 
entities in the US.53 For example, insulin glargine was approved by the U.S. Food and Drug 
Administration (FDA) on 16 December 2015 via the Food, Drug, and Cosmetic Act 
(FD&C Act), section 505(b)(2), new drug application (NDA) pathway system and not as a 
biosimilar.54 Presently, there are three follow-on biologic insulins approved by the FDA, 
and two are available for sale. Those insulins were introduced to the market with a 15% 
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discount on the wholesale acquisition cost of the brand. 54   Despite the presence of follow-
on insulins (biosimilars) in the US market, insulin prices remain high.  The increased 
competition between insulin manufacturers might bring down the price of insulin, but most 
likely, not below 50% of the initial price.55   However, the US may have a similar experience 
to the UK, where the first follow-on insulin glargine was recently introduced, and it has a 
list price that is only 15% lower than of the originator insulin product. 
Increases in insulin product prices affect third-party payers, especially Medicare 
and the Medicaid programs that provide prescription coverage to the majority of older 
adults. High prices also places an economic burden on patients due to increasing out-of-
pocket costs, which negatively affect adherence to drug therapy.56 Non-adherence to 
therapy negatively impacts clinical outcomes, increases the risks of diabetic complications 
and related-hospitalizations,12,16 and leads to increased total health care expenditures.57, 58  
Therefore, providers, pharmacies, and health plans should discuss the cost of insulin 
preparations with diabetic patients to help understand the advantages, disadvantages, and 
financial implications of potential insulin preparations. Taking cost into consideration 
during the prescription process can push providers and patients to decide to follow more 
cost-conscious treatment routes, instead of which form of insulin is best suited for a 
patient’s medical needs. Furthermore, there is a need for more transparency throughout the 
insulin supply chain. List price for insulins could more closely reflect net price, and rebates 
based on list price could be minimized. The current payment system should rely less on 
rebates, discounts, and fees based on list price. The FDA also should continue to streamline 
the process to bring more biosimilar insulins to market.  
 
29 
 
 
This study has some potential limitations. We assessed the price of insulin products 
marketed in the US. Thus, the results do not apply to other antidiabetic medications. The 
AWP is reported by the manufacturer and does not represent the final net acquisition cost 
paid for drugs in the US since discounts and rebates are not deducted from the AWP. The 
NADAC is reported by community pharmacies and does not include rebates that 
pharmaceutical companies pay to Medicaid, managed care organizations, health care 
organizations, and other payers. Additionally, annual trends in insulin utilization, changes 
in insulin coverage by public and private insurers, and changes in insulin utilization 
guidelines are not readily available for the study period 1980- July 2019. Our insulin price 
trends analysis did not control for these variables, which may affect our analysis.  
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7. Conclusion  
 
Prices of insulin products increased significantly, regardless of the presence of 
biosimilar competition between 1983 and July 2019. This study found substantial 
differences in insulin manufacturer prices, acquisition cost estimations, and reimbursement 
prices in the public and private US healthcare system. Pharmaceutical companies’ listed 
prices were higher than the pharmacy estimated acquisition costs, and the amount used for 
reimbursement. The prices paid by the federal government were substantially lower than 
the prices paid in the private sector.  
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Appendix 1a.   insulin products marketed in the US in July 2019 
Class Active Ingredient Proprietary Name Applicant Holder Mkt.Status Approval Date 
Fast-Acting insulin  insulin aspart Fiasp Novo Nordisk Inc RX Sep 29, 2017 
insulin aspart Fiasp Flextouch Novo Nordisk Inc RX Sep 29, 2017 
insulin aspart Fiasp Penfill Novo Nordisk Inc RX Sep 24, 2018 
insulin aspart recombinant Novolog Novo Nordisk Inc RX Jun 7, 2000 
insulin aspart recombinant Novolog Flexpen Novo Nordisk Inc RX Jan 19, 2001 
insulin aspart recombinant Novolog Penfill Novo Nordisk Inc RX Jun 7, 2000 
insulin glulisine recombinant Apidra Sanofi Aventis Us Llc RX Apr 16, 2004 
insulin glulisine recombinant Apidra Solostar Sanofi Aventis Us Llc RX Feb 24, 2009 
insulin lispro Admelog** Sanofi-Aventis Us Llc RX Oct 19, 2018 
insulin lispro Admelog** Sanofi-Aventis Us Llc RX Dec 11, 2017 
insulin lispro Admelog Solostar** Sanofi-Aventis Us Llc RX Dec 11, 2017 
insulin lispro recombinant Humalog Eli Lilly And Co RX Jun 14, 1996 
insulin lispro recombinant Humalog Kwikpen Eli Lilly And Co RX Sep 6, 2007 
insulin lispro recombinant Humalog Kwikpen Eli Lilly And Co RX May 26, 2015 
Short-acting insulin 
 
insulin human Humulin R Eli Lilly And Co RX Mar 31, 1994 
insulin human Humulin R Kwikpen Eli Lilly And Co RX Dec 29, 2015 
insulin recombinant human Humulin R Eli Lilly And Co OTC Oct 28, 1982 
insulin recombinant human Humulin R Pen Eli Lilly And Co OTC Aug 6, 1998 
insulin recombinant human Novolin R Novo Nordisk Inc OTC Jun 25, 1991 
Intermediate- Acting 
insulin  
insulin aspart protamine recombinant; insulin 
aspart recombinant 
Novolog Mix 70/30 Novo Nordisk Inc RX Nov 1, 2001 
insulin aspart protamine recombinant; insulin 
aspart recombinant 
Novolog Mix 70/30 Flexpen Novo Nordisk Inc RX May 3, 2002 
insulin susp isophane recombinant human Humulin N Eli Lilly And Co RX Oct 28, 1982 
insulin susp isophane recombinant human Novolin N Novo Nordisk Inc RX Jul 1, 1991 
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Appendix 1b.   insulin products marketed in the US in July 2019 
** Follow-on (biosimilar) insulin 
 
Class Active Ingredient Proprietary Name Applicant Holder Mkt.Status Approval Date 
Long-Acting insulin 
 
 
 
  
insulin degludec Tresiba Novo Nordisk Inc RX Sep 25, 2015 
insulin degludec Tresiba Novo Nordisk Inc RX Sep 25, 2015 
insulin degludec Tresiba Novo Nordisk Inc RX Nov 21, 2018 
insulin detemir recombinant Levemir Novo Nordisk Inc RX Jun 16, 2005 
insulin detemir recombinant Levemir Flextouch Novo Nordisk Inc RX Oct 31, 2013 
insulin glargine Basaglar** Eli Lilly And Co RX Dec 16, 2015 
insulin glargine recombinant Lantus Sanofi Aventis Us Llc RX Apr 20, 2000 
insulin glargine recombinant Lantus Solostar Sanofi Aventis Us Llc RX Apr 27, 2007 
insulin glargine recombinant Toujeo Max Solostar Sanofi Us Services Inc RX Mar 26, 2018 
insulin glargine recombinant Toujeo Solostar Sanofi Us Services Inc RX Feb 25, 2015 
Premixed; Intermediate-
or Long-Acting 
Combined with Fast- or 
Short-Acting insulin –or 
non-insulin drug 
  
insulin degludec; liraglutide Xultophy 100/3.6 Novo Nordisk Inc RX Nov 21, 2016 
insulin glargine; lixisenatide Soliqua 100/33 Sanofi-Aventis Us Llc RX Nov 21, 2016 
insulin lispro protamine recombinant; insulin 
lispro recombinant 
Humalog Mix 50/50 Eli Lilly And Co RX Dec 22, 1999 
insulin lispro protamine recombinant; insulin 
lispro recombinant 
Humalog Mix 50/50 Kwikpen Eli Lilly And Co RX Sep 6, 2007 
insulin lispro protamine recombinant; insulin 
lispro recombinant 
Humalog Mix 75/25 Eli Lilly And Co RX Dec 22, 1999 
insulin lispro protamine recombinant; insulin 
lispro recombinant 
Humalog Mix 75/25 Kwikpen Eli Lilly And Co RX Sep 6, 2007 
insulin recombinant human; insulin susp 
isophane recombinant human 
Humulin 70/30 Eli Lilly And Co OTC Apr 25, 1989 
insulin recombinant human; insulin susp 
isophane recombinant human 
Humulin 70/30 Pen Eli Lilly And Co OTC Aug 6, 1998 
insulin recombinant human; insulin susp 
isophane recombinant human 
Novolin 70/30 Novo Nordisk Inc OTC Jun 25, 1991 
Inhaled insulins insulin recombinant human Afrezza Mannkind Corp RX Jun 27, 2014 
insulin recombinant human Afrezza Mannkind Corp RX Jun 27, 2014 
insulin recombinant human Afrezza Mannkind Corp RX Apr 17, 2015 
